ZO-SA0 PhaseIII clinical trial

Zeria Pharmaceutical Co., Ltd.0 个研究点目标入组 60 人开始时间: 2014年1月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients with cardiovascular disease.
•Out-patients who signed a written informed consent.
•If patient age is under 20 years old, a written informed consent have to be obtained from both participant and his/her parent(s).

•Patients with or have a history of heart failure, renal failure, nephrotic syndrome, hepatic cirrhosis, thyroid disease
•Patients with or have a history of lymphoedema, or patients have a history of pelvic surgery
•Patients with allergic oedema or drug-induced oedema
•Patients with or have a history of peripheral arterial disease, acute phlebitis, congenital vascular anomaly
•Patients with or a history of venous thromboembolism
•Patients who had lower leg surgery, venous sclerotherapy, or compression therapy within 4 weeks before receipt of informed consent
•Patients who received treatment indicated for lower leg oedema, or treatment to improve lower leg oedema or subjective symptoms associated with lower leg oedema within 4 weeks before receipt of informed consent

发起方